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Background: Elastin is an essential component of selected connective tissues that provides a unique physiological
elasticity. Elastin may be considered a signature protein of lungs where matrix metalloprotease (MMP) -9-and -12,
may be considered the signature proteases of the macrophages, which in part are responsible for tissue damage
during disease progression. Thus, we hypothesized that a MMP-9/-12 generated fragment of elastin may be a
relevant biochemical maker for lung diseases.
Methods: Elastin fragments were identified by mass-spectrometry and one sequence, generated by MMP-9 and -12
(ELN-441), was selected for monoclonal antibody generation and used in the development of an ELISA. Soluble and
insoluble elastin from lung was cleaved in vitro and the time-dependent release of fragments was assessed in the
ELN-441 assay. The release of ELN-441 in human serum from patients with chronic obstructive pulmonary disease
(COPD) (n = 10) and idiopathic pulmonary fibrosis (IPF) (n = 29) were compared to healthy matched
controls (n = 11).
Results: The sequence ELN-441 was exclusively generated by MMP-9 and -12 and was time-dependently released
from soluble lung elastin. ELN-441 levels were 287% higher in patients diagnosed with COPD (p< 0.001) and 124%
higher in IPF patients (p< 0.0001) compared with controls. ELN-441 had better diagnostic value in COPD patients
(AUC 97%, p = 0.001) than in IPF patients (AUC 90%, p = 0.0001). The odds ratios for differentiating controls from
COPD or IPF were 24 [2.06–280] for COPD and 50 [2.64–934] for IPF.
Conclusions: MMP-9 and -12 time-dependently released the ELN-441 epitope from elastin. This fragment was
elevated in serum from patients with the lung diseases IPF and COPD, however these data needs to be validated in
larger clinical settings.
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Elastin plays a critical role in the development of the car-
diovascular, skin and respiratory system, as demonstrated
when deletions and mutations in the elastic fibers result in
supravalvular aortic stenosis (SVAS), William-Beuren syn-
drome (WBS) or cutis laxa (CL) [1,2]. SVAS and WBS are
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reproduction in any medium, provided the ornarrowing of the aorta, peripheral pulmonary arteries, cor-
onary and other major arteries, whereas CL results in an
impaired vascular system and a severe dermal phenotype
due to dermal inflammation and destruction of the elastic
fibres [2,3].
The architecture of elastic fibres is tissue-specific reflect-
ing the specific function of different tissues [4]. In general,
elastic fibres are a major class of extracellular matrix mole-
cules that are abundant in connective tissues. Elastic fibres
are composed of elastin surrounded by a mantle of
fibrillin-rich microfibrils. Elastin is formed by linking manyral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to create a massive insoluble, durable cross-linked array.
Tropoelastin is characterized by hydrophobic mobile
regions bounded by cross-links between lysine residues, re-
ferred as desmosine and isodesmosine, which stabilize the
polymerized insoluble elastin and are essential for the elas-
ticity [4].
In the lung, elastin fibres create a thin highly branched
network throughout the respiratory tree to support the ex-
pansion and recoil of the alveoli during breathing. In the
aorta and arteries, the elastin fibres are present in the med-
ial layer, and form concentric fenestrated lamellae giving
elasticity and resilience to the vessel walls [4]. Elastin fibres
are very long-lasting with little turnover in healthy tissues
[5]. However, various proteases such as matrix metallopro-
teinases (MMPs) and serine proteases are able to cleave
elastin fibres by damaging the microfibrils and the elastin
core [5-7], resulting in loss of elasticity. This loss of elasti-
city is a pathological feature of a number of degenerative
and inflammatory diseases including vascular aneurysms
[5,8] and chronic obstructive pulmonary disease (COPD)
with co-existing emphysema [9,10]. For instance, deletion
of the elastin gene in mice revealed lungs with
emphysema-like lesions [11].
COPD is characterized by co-existence of emphysema,
inflammation and narrowing in the small conducting air-
ways and chronic changes in lung parenchyma which de-
velop over many years. Idiopathic pulmonary fibrosis (IPF)
is a progressive interstitial lung disease characterized by
fibroblast proliferation and extracellular remodeling [12,13].
Lack of sensitive parameters of lung injury and destruction
make quick evaluation of lung diseases difficult, which
highlights the need for accurate and precise biochemical
markers for diagnosis and prognosis, as well as early estab-
lishment of efficacy. Tools which have been suggested to in-
dicate impaired physiological lung function, are computed
tomography analysis and biochemical measurements of
extracellular matrix degradation [14]. The pathogenesis of
lung diseases such as COPD and IPF involves an inflamma-
tory response [12,13], and tissue turnover is mediated in
part by activated macrophages, which secrete their signa-
ture panel of proteases, including MMP-9 and -12
[12,13,15,16]. Desmosine and isodesmosine have been ex-
tensively discussed as potential indicators of elevated lung
elastin fiber turnover, but their clinical validity and utility in
urine and blood remains unproven. The major reasons are
issues related to analytical validity of assays and lack of large
longitudinal studies predicting progression and reflecting
changes induced by effective treatment. These lysine resi-
dues are therefore still far from being considered as reliable
biomarkers for COPD and IPF. [14,17,18]
Recently proteolytic generation of pathological- and
tissue-specific fragments of proteins has received increased
attention [19] as a potential marker of COPD and IPF.These protein fragments, referred to as neoepitopes or
protein fingerprints [20,21], have proven to be more accur-
ate predictors of disease than their unmodified intact pro-
tein origin [19]. For example, a type III collagen fragment
generated by MMPs has been shown to be a marker for
generalized and liver fibrosis [22,23], type II collagen deg-
radation by MMPs has been demonstrated to be a marker
for osteoarthritis and rheumatoid arthritis [24] and finally
type I collagen fragments generated by cathepsin K, has
been approved by the US Food and Drug Administration
as a diagnostic tool for measuring and monitoring bone re-
sorption [19].
Endopeptidases, such as MMPs, aggrecanases (ADAMTSs)
and cathepsins, play a pivotal role in the degradation of
extracellular matrix proteins in many diseases [25]. Espe-
cially MMP-9 and MMP-12 have been associated with elas-
tin degradation and hence with cardiovascular [26] and
respiratory diseases [15,16]. Our hypothesis was that elastin
degradation by MMP-9 and -12, may provide information
to aid diagnosis and progression of respiratory diseases.
The aims were to investigate the cleavage-type and kinet-
ics of elastin and to develop an ELISA for quantitative as-
sessment of MMP-degraded elastin. Finally the hypothesis
was tested in a preliminary clinical setting investigating the
discriminative diagnostic power.Methods
In vitro cleavage of purified elastin from human tissue
Purified elastin from human aorta (Sigma Aldrich, pre-
pared using the method described by Starcher et al. [27])
was cleaved with MMP-1, MMP-9, cathepsin K, cathepsin
S (Calbiochem, VWR), MMP-3, MMP-8, MMP-12
(Abcam), ADAMTS-1, -4 and -8 (Abnova). The proteases
were activated according to the manufacturers’s instruc-
tions. Each cleavage was performed separately by mixing
200 μg elastin/tissue and 2 μg of activated enzymes in
MMP buffer (100 mM Tris–HCl, 100 mM NaCl, 10 mM
CaCl2, 2 mM ZnOAc, pH 8.0), cathepsin buffer (50 mM
NaOAc, 20 mM L-cystine, pH=5.5) or aggrecanase buffer
(50 mM Tris–HCl, 10 mM NaCl, 10 mM CaCl2, pH=7.5).
As the control, 200 μg elastin was mixed with MMP buffer
only. The final concentration of elastin before cleavage was
0.33 mg/mL. Each aliquot was incubated for 2, 4, 24, 48,
72 and 169 hours at 37°C. All MMP cleavages were termi-
nated using GM6001 (Sigma-Aldrich) and all cathepsin
and aggrecanase cleavages using E64 (Sigma-Aldrich). Fi-
nally the cleavage was verified by visualization using the
SilverXpress
W
Silver Staining Kit (Invitrogen) according to
the manufacturers’ instructions.
Using the same procedure as described above, purified
elastin from non-soluble lung aorta (Sigma Aldrich, pre-
pared using the method described by Starcher et al. [27]),
soluble aorta and soluble lung (Sigma Aldrich, prepared
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cleaved with MMP-9 and -12.
Human vascular tissue (atheroma-aorta, Biocat, Heidel-
berg, Germany) was cleaved by MMP-9 as described by
Zhen et al. [25]. Digestion was carried out at 37°C by add-
ing 1 μg activated MMP-9 in 250 μL digestion buffer (1 M
Tris buffer (pH 7.4), NaCl, CaCl2, ZnOAc). Supernatants
were removed on days 1, 3, 7 and 10 and frozen at −80°C.
At each time point, MMP-9 in digestion buffer was added
to the vascular wall sample after removing the superna-
tants and incubation was continued.
Peptide identification by mass spectrometry
Analysis of the cleavage products of elastin purified from
human aorta and of human vascular wall were per-
formed in three different laboratories: A) Nordic Bio-
science Beijing,China B) Department of Biochemistry and
Molecular Biology at the University of Southern Denmark,
Denmark, and C) as described by Zhen et al. [25]. The pep-
tides were purified and desalted using reversed phase (RP)
micro-columns (Applied Biosystems) prior to nanoLC-MS-
MS analysis as described in the literature [29]. The purified
peptides were re-suspended in 100% formic acid, diluted
with H2O and loaded directly onto a 18 cm RP capillary
column using a nano-Easy-LC system (Proxeon, Thermo
Scientific). The peptides were eluted using a gradient from
100% phase A (0.1% formic acid) to 35% phase B (0.1% for-
mic acid, 95% acetonitrile) over 43 min directly into an
LTQ-Orbitrap XL mass spectrometer (Thermo Scientific).
For each MS scan (Orbitrap), acquired t a resolution of
60000, 300–1800 Da range, the five most abundant precur-
sor ions were selected for fragmentation (CID). The raw
data files were converted to mgf files and searched in Mas-
cot 2.2 software using Proteome Discoverer (Thermo Sci-
entific). Peptides with a mascot probability score p< 0.05
were further analysed.
Selection of peptide for immunizations
The first six amino acids of each free end of the sequences
identified by MS were regarded as a neoepitope generated
by the protease in question. All protease-generated
sequences were analyzed for homology and distance to
other cleavage sites and then blasted for homology using
the NPS@: network protein sequence analysis [30].
Immunization procedure
Six 4–6 week old Balb/C mice were immunized subcutane-
ously in the abdomen with 200 μL emulsified antigen
(50 μg per immunization) using Freund’s incomplete adju-
vant (KLH-CGG-VPGVGISPEA (Chinese Peptide Com-
pany, Beijing, China)). Immunizations were continued
until stable titer levels were obtained. The mouse with the
highest titer was selected for fusion and boosted intraven-
ously with 50 μg immunogen in 100 μL 0.9% sodiumchloride solution three days before isolation of the spleen
for cell fusion. The fusion procedure has been described
elsewhere [31]. The mouse work was approved by the
Beijing laboratory animal administration office under
approval number 200911250.
Characterization of clones
The sequence VPGVGISPEA, named ELN-441, was
selected for antibody generation. Native reactivity and pep-
tide binding of the generated monoclonal antibodies were
evaluated by displacement of human serum in a prelimin-
ary indirect ELISA using biotinylated peptides (Biotin-
VPGVGISPEA) on a streptavidin-coated microtitre plate
and the supernatant from the growing monoclonal hybri-
doma. Tested were the specificities of clones to the free
peptide (VPGVGISPEA), a non-sense peptide, and the
elongated peptide (VPGVGISPEAQ). Isotyping of the
monoclonal antibodies was performed using the Clonotyp-
ing System-HRP kit (Southern Biotech). The selected
clones were purified using Protein G columns according to
manufacturer’s instructions (GE Healthcare Life Science).
Assay protocol
The selected monoclonal antibody was labeled with horse-
radish peroxidase (HRP) using the Lightning link HRP la-
beling kit according to the instructions of the manufacturer
(Innovabioscience). A 96-well streptavidin plate was coated
with 0.4 ng/mL Biotin-VPGVGISPEA dissolved in assay
buffer (25 mM Tris, 1% BSA, 0.1% Tween-20, pH 7.4) and
incubated for 30 minutes at 20°C. 20 μL of free peptide cali-
brator or sample were added in duplicate to appropriate
wells, followed by 100 μL of conjugated monoclonal anti-
body and incubated for 1 hour at 20°C. Finally, 100 μL tet-
ramethylbenzinidine (TMB) (Kem-En-Tec) was added and
the plate was incubated for 15 minutes at 20°C in the dark.
All the above incubation steps included shaking at
300 rpm. After each incubation step the plate was washed
five times in washing buffer (20 mM Tris, 50 mM NaCl,
pH 7.2). The TMB reaction was stopped by adding 100 μL
of stopping solution (1% HCl) and measured at 450 nm
with 650 nm as the reference. A master calibrator prepared
from the synthetic-free peptide accurately quantified by
amino acid analysis was used as a calibration curve and
plotted using a 4-parametric mathematical fit model.
Technical evaluation and specificity
From 2-fold dilutions of quality control (QC) serum and
plasma samples, linearity was calculated as a percentage of
recovery of the 100% sample. The lower limit of detection
was determined from 21 zero serum samples (i.e. buffer)
and calculated as the mean+3X standard deviation. The
inter- and intra-assay variation was determined by 12 inde-
pendent runs of 8 QC serum samples, with each run con-
sisting of two replicas of double determinations. The
Skjøt-Arkil et al. BMC Pulmonary Medicine 2012, 12:34 Page 4 of 12
http://www.biomedcentral.com/1471-2466/12/34stability of serum was measured using three serum sam-
ples, which were frozen and thawed between one and 10
times.
The antibody ELN-441 was evaluated using the materials
described under “In vitro cleavage”, where elastin was
cleaved by different MMPs, cathepsins and aggrecanases.
The samples were diluted 1:10 in the ELISA.
Clinical validation of ELN-441
ELN-441 levels were measured in serum from patients
diagnosed with COPD (n=10) and IPF (n=29) and com-
pared with controls (n=11). The COPD and IPF serum
samples were obtained as a part of the “lung tissue research
consortium” (www.ltrcpublic.com). The local IRB evalu-
ated the study and concluded that due to the proper de-
identification of samples and patients by the LTRC, an
approval from the IRB was not required for this work. The
controls were derived from a previously described study
[32,33]. The samples were diluted 1:2 in the ELN-441
assay.
Statistics
Serum levels of ELN-441 in COPD/IPF patients and con-
trols were compared using two-sided non-parametric
Wilcoxon rank sum test. Area under the curve was calcu-
lated using the Receiver Operating Characteristic (ROC).
The likelihood of patients having ELN-441 was investi-
gated as an odds ratio, extrapolated from weighted levels,
with the lowest value in the population being set at 0 and
the highest at 1, and all subjects classified as having normal
(within the 1.8xSD+mean of the normal population) or
high (>1.8xSD + mean) levels of the biomarker. Results
were considered statistically significant if p< 0.05.
Results
Analysis of protease generated elastin degradation
Analysis of cleavage sites of purified elastin from human
aorta is shown in Table 1. A total of 114 identified different
fragments were generated: 6 by MMP-1, 7 by MMP-3, 11
by MMP-8, 4 by MMP-9, 10 by cathepsin K, 12 by cathe-
psin S, 24 by ADAMTS-1, 19 by ADAMTS-4 and 21 by
ADAMTS-8. The majority (73%) of the cleavages involved
alanine (A), valine (V) or glycine (G). Glycine was involved
in most (40%) of the cleavages. Half of the amino acids
involved in the cleavage sites were hydrophobic (47%) and
the other half hydrophilic (53%), however most cleavages
of hydrophobic amino acids took place at the amino acids
NH2-group (67%) and opposite for the hydrophilic amino
acids (73%).
Cleavages between glycine-valine and glycine-alanine
were predominant in the N-terminal of the identified pep-
tides, whereas glycine-glycine and lysine-alanine were
favored in the C-terminal end of the peptides (data not
shown). Glycine-valine cleavages were created by all theproteases but more commonly by MMPs. The glycine-
glycine cleavage site most frequently involved MMP-1
(Figure 1). ADAMTS-8 was the only protease to cleave
between leucine-alanine, while arginine-phenylalanine
cleavages were only produced by ADAMTS-1 and -8
(Figure 1). Lysine-alanine and glycine-alanine cleavages
were shared among the proteases.Selection of the most promising neoepitope
A selection of the cleavage kinetics of MMP-9 and -12
generated fragments analysed by laboratory B, is illustrated
in Table 2. A total of 416 different peptides were identified
of which 132 were identified in elastin preparations with
no added proteases. Some of the peptides were only gener-
ated by one of the MMPs, others by both MMP-9 and -12.
The time of digestion varied with some peptides being gen-
erated immediately, others after days of incubation, and
some peptides continued to be degraded with subsequent
incubations.
The length of the identified protease-generated peptides
was between 10 and 45 amino acids. They were tested for
homology and cross-reactivity to other proteins to select
sequences that were unique and the most representative of
elastin degradation. The sequence selected was
VPGVGISPEA# since it was identified by LC-MS/MS in
in vitro MMP-9 and -12 cleaved elastin purified from
human aorta (Table 3) and was also identified in MMP-9
digested elastin from the vascular wall (laboratory C)
(Table 4). The sequence VPGVGISPEA# was also identified
in a single peptide generated by MMP-1. The sequence had
a very conservative C-terminal and was found in more than
one peptide. The sequence was named ‘ELN-441’ due to the
cleavage site at alanine with amino acid number 441. ELN-
441 was selected for immunization and antibody generation.Assay development and validation
The requirements for selecting the monoclonal antibodies
for ELISA development were I) IgG subtype, II) specificity
towards the neoepitope and not the elongated peptide or
uncleaved elastin, III) native reactivity towards diseased
human body fluids and not only to the synthetic peptide
and IV) acceptable dilution recoveries in human body
fluids. Based on these requirements an antibody recogniz-
ing the sequence VPGVGISPEA was selected. The mono-
clonal antibody did not show any affinity toward either the
elongated peptides or the uncleaved elastin (Figure 2A
and C). The native reactivity towards diseased human
serum and plasma was high and the signal was almost
inhibited completely (Figure 2B). These findings were con-
sistent in repeated batches.
The results of the technical evaluation of the assay
known as “ELM” are in Table 5 and show a technically
robust assay with dilution recovery within the
Table 1 Analysis of the individual amino acids involved in the cleavages of elastin
Hydrophobocity Amino acid type Share of elastin* No. of cleavages in the N-terminal No. of cleavages in the C-terminal Percentage of cleavages
R-COOH# #NH2-R R-COOH# #NH2-R R-COOH# #NH2-R Total
Hydrofobic A 21% 15 30 16 36 14% 29% 21%
P 13% 5 5 4 4 4% 4% 4%
V 12% 5 37 2 12 3% 22% 12%
L 7% 8 5 3 2 5% 3% 4%
I 2% – 3 – 1 <1% 2% 1%
F 2% 4 3 – 15 2% 8% 5%
Total 57% 27% 67% 47%
Hydrophilic G 28% 71 22 56 33 56% 24% 40%
K 4% 3 – 21 – 11% <1% 5%
S 2% – – – 2 <1% 1% <1%
Y 2% 1 3 – 2 <1% 2% 1%
T 2% 1 1 – 5 <1% 3% 2%
R 2% – 4 12 – <1% 2% 4%
Q 1% – – – 2 <1% 1% <1%
Total 43% 73% 33% 53%
114 different peptides were identified. Two cleavage sites (one in the N-terminal and one in the C-terminal) are involved in generating each of these peptides. Each of these cleavage sites involve two amino acids
(one cleaved at the NH2-group and the other one at the COOH-group). Arrow (#) indicates the cleavage site.
*The content of M, E, D, H and C in elastin are ≤1% and not included in the table.
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Figure 1 The distribution of type of cleavage sites in the presence of various proteases. N indicates number of total cleavage sites for
each protease and n indicates number of type of cleavage site.
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sion was acceptable with low inter- and intra-assay
variation.Generation of ELN-441 is dependent on cleavage time
and solubility of tissue
By LC-MS/MS analysis the sequence VPGVGISPEA was
identified as being generated by MMP-9 and -12, and from
the ELISA characterization it was confirmed that these
MMPs were able to generate the fragment in amounts high
enough to be detected by the ELISA (Figures 2C and 3).
The cleavages were observed to be dependent on the solu-
bility of the tissue and the type of protease. MMP-9 and -12
generated equal amounts of ELN-441 when added to sol-
uble lung (Figure 3A), but when added to insoluble lung
only MMP-12 was able to generate ELN-441 and in much
lower quantities (Figure 3B). The cleavage fragment was
released in a time-dependent manner as seen in (Figure 3C).ELN-441 is elevated in patients with COPD and IPF
Levels of the MMP-9 and MMP-12 generated neoepitope
ELN-441 were significantly higher in serum from patients
diagnosed with COPD (p< 0.0003) and with IPF (p< 0.0001)
compared with controls (Figure 4A).Diagnostic value of ELN-441 to differentiate between
COPD and IPF patients and controls
To investigate the diagnostic value of ELN-441, the ROC
curves were produced and the area under the curve (AUC)
calculated (Figure 4B). ELN-441 had the best diagnostic
value in COPD patients (AUC 97%, p=0.00025), with
lower diagnostic value in IPF patients (AUC 90%,
p= 0.00011). The odds ratios (Figure 4C) for differentiating
controls from COPD and from IPF patients indicate that
COPD diagnosing had the highest value (24, [2.06–280])
compared with IPF diagnosing (50, [3.64–934]). The con-
trols were normally distributed and the upper limit of nor-
mal was mean+1.8xSD.
Discussion
This study provides the following important information on
the diagnosis and progression of important lung diseases:
1) Elastin is degraded by different proteases at different
times. This degradation pattern adds to information
already described by others[34-36]. We selected a
specific neoepitope as a candidate novel biomarker
of lung disease, and developed an ELISA (ELM) for
quantifying this unique target. To our knowledge,
this assay is the first to quantify MMP degradation
Table 2 Examples of cleavage kinetics of MMP-9 and -12 generated peptides identified by MS in elastin from
human aorta
Amino acid no. Identified peptides in elastin from aorta MMP-9 cleaved (hours) MMP-12 cleaved (hours)
0 2 24 48 72 ≥169 2 24 48 72 ≥169
041-051 VFYPGAGLGAL x x
041-057 VFYPGAGLGALGGGALG x x X x x
041-059 VFYPGAGLGALGGGALGPG x x X
085-102 VTFPGALVPGGVADAAAA x x
141-159 VPGVGLPGVYPGGVLPGAR x x x X x x x x x x x
158-164 ARFPGVG x
229-241 GYGPGGVAGAAGK x x x
230-241 YGPGGVAGAAGK x x X x x x x
280-293 AGVPGVPGAIPGIG x X x x x x x
281-294 GVPGVPGAIPGIGG x x x x x x
302-312 AAAAAAAAAAK x
327-339 PGFGPGVVGVPGA x x x x
384-408 GARPGVGVGGIPTYGVGAGGFPGFG x x X x x
385-392 ARPGVGVG x x x
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human fluids. This tool may provide value for other
researchers and for the characterization of patients.
2) The ELN-441 neoepitope was generated by MMP-9
and -12 in a time dependent manner for soluble
elastin, while in the case of insoluble elastin, only
MMP-12 was able to generate the fragment.
3) The selected neoepitope of elastin was based on our
MS analysis cleavage pattern by MMP-12, which is
the protease known to be highly expressed in
macrophages during lung inflammation.
4) By preliminary analysis in a limited number of
patients, the ELM degradation marker exhibited
highly specific diagnostic power, in particular for
COPD with an AUC over 97%, and IPF with an
AUC over 90%.
This study showed that elastin was degradable by MMPs,
cathepsins as well as aggrecanases. The bulk of the identi-
fied peptides from in vitro cleaved soluble elastin was how-
ever generated by aggrecanases. This is an important
observation as a recent publication highlighted the aggre-
canases as important molecules in lung diseases [37], and
the fact that different proteases have different molecularTable 3 Peptides cleaved at amino acid no. 441 identified by
by MMP-9 and -12
Amino acid no. Identified peptides in elastin from aorta MM
2 24
423-441 VGGVPGVGGVPGVGISPEA
425-441 GVPGVGGVPGVGISPEA xcharacteristics [38]. It is well appreciated in cartilage path-
ologies that aggrecanase and MMP mediated cartilage de-
struction provide different molecular information [49].
Due to the sensitivity of the MS–technology, we identified
elastin in the non-proteolytical fraction that was degraded
in vitro. Whether this may indicate hot-spots for protein
degradation, instability or artifacts during the purification
procedure remains to be investigated. Interestingly, differ-
ent numbers and fragments of identified peptides were
obtained in the three different MS-laboratories. This may
reflect different equipment and emphasizes the fragility of
the current approach, and the necessity for cross-
validation by multiple runs of the identified fragments in
different cleavages by different equipments.
Although elastin fragments generated by aggrecanases
and cathepsins were identified and may serve as biomarker
targets for other indications, our study focused on the ac-
tivity of MMP-9 and -12 because these proteases are
expressed in respiratory diseases [15,16]. To some extent
the two MMPs have a similar degradation profile, cleaving
at many of the same sites, although some unique sites were
also identified. Measuring the release of ELN-441 from
elastin-rich tissues emphasized that only MMP-12, and not
MMP-9, is able to degrade elastin from insoluble lung andMS in elastin purified from human aorta cleaved in vitro
P-9 cleaved (hours) MMP-12 cleaved (hours)
48 72 ≥169 2 24 48 72 ≥169
x
x x x
Table 4 Peptides cleaved at amino acid no. 441 identified by MS in MS in human vascular wall cleaved in vitro by
MMP9
Amino acid no. Identified peptide in vascular wall MMP-9 cleaved (hours)
24 72 168 240
409-441 VGVGGIPGVAGVPSVGGVPGVGGVPGVGISPEA x
417-441 VAGVPSVGGVPGVGGVPGVGISPEA x x
422-441 SVGGVPGVGGVPGVGISPEA x
423-441 VGGVPGVGGVPGVGISPEA x
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MMP-9.
Of the elastin cleavages, 73% involved alanine, valine and
glycine, of which glycine was predominant. This was as
expected, alanine, valine and glycine compose 3 out of the
four main amino acids in elastin. The fourth amino acid is
proline. Alanine, valine and glycine are the amino acids
with the shortest molecular chain leading to the smallest
steric hindrance and probably easy accessible. This might
be the reason for the reduced cleavage at proline, since it
contains a pyrrolidin ring. Half of the amino acids making
up elastin are hydrophobic which matches the outcome
that half of the amino acids involved in the cleavage of
elastin are hydrophobic. Interestingly the majority of the
cleavages of the hydrophobic amino acids took place at the
NH2-group of the amino acid. The opposite was observed
for the hydrophilic amino acids in which the COOH-group
was the preferred cleavage site. Cleavage sites involving gly-
cine specially glycine-valine and glycine-glycine are not
protease specific since aggrecanases, cathepsins and MMPs
recognize these sites. Aggrecanases differ from the other
proteases by degrading elastin at different cleavage sites
such as between leucine-alanine and arginine-
phenylalanine. Aggrecanase generated neoepitopes mayFigure 2 Characterization of the ELN-441 monoclonal antibody. ELISA
elongated peptide, B) the free peptide and the native human serum and p
indicated by the dotted lines, C) the in vitro cleaved elastin from aorta with
1:80 and so on as indicated by the dotted lines.therefore have a different diagnostic profile than for ex-
ample MMPs. The cleavage products are dependent on in-
cubation time, amount of protease and the stability of the
peptide, as observed by others [40].
Elastin degradation has been investigated by several
groups [14,41-45] conducting analyses of the cleavage pat-
tern and of proteases involved as a consequence of inflam-
mation and macrophage activity. When analyzing the
MMP-12 degradation of tropoelastin Taddese et al. and
Heinz et al. both identified the ELN-441 fragment [34,36].
Barroso et al. did not identify ELN-441, but observed that
the amount of degradation peptides is highly related to the
amount of protease [40]. Furthermore, it has been shown
that elastin degradation fragments, in particular a MMP-12
generated repeated sequence fragment, acts as a chemo-
attractant for monocytes and fibroblasts in vitro [41,42]
and that autoimmune response to elastin fragments has
been identified [46].
A battery of proteases, in particular MMPs, has been
shown to be important mediators in lung disease. MMP
and neutrophil elastase expression was investigated in
patients with COPD and healthy controls using bronchoal-
veolar lavage fluid to analyse macrophage expression of the
different MMPs [47]. It was found that MMP-9, MMP-8,showing percent inhibition of the signal of: A) the free peptide and
lasma samples which were run diluted 1:2, 1:4 and so forth as
and without MMP-9 and -12. The materials were run diluted 1:40,
Table 5 Summary table of the technical validation of ELM
Technical validation step ELN-441
Target MMP degradation of human elastin
Detection range 0,484–125 ng/mL
Dilution range of serum samples 1:2, 1:3 and 1:4 is recommended
Dilution range of plasma samples 1:2, 1:3 and 1:4 is recommended
Dilution recovery of human serum* 91%
Dilution recovery of human plasma* 95%
Intra-assay variation** 9.44%
Inter-assay variation** 13.8%
Analyte stability*** 103%
*Percentage dilution recovery was calculated as the mean of 5 human
samples diluted 1:2 and 1:4. **Inter- and intra-assay validation was calculated
as the mean variation between 8 individual determinations of each human
serum sample. ***The stability of the analyte (human serum) was calculated as
the mean of three different serum samples were tested after freeze/thaw for
one to 10 times.
Skjøt-Arkil et al. BMC Pulmonary Medicine 2012, 12:34 Page 9 of 12
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cantly increased in COPD patients compared with healthy
controls. Another group also showed that MMP-12 is ne-
cessary for macrophage recruitment in the lungs of smoke-
exposed mice since MMP-12 knockout mice failed to de-
velop inflammation in response to cigarette smoke [48].
Interestingly, a study investigated the ability of human and
mouse monocyte-derived macrophages to degrade elastin
ex vivo, concluded that MMP-12 may not be an elastolytic
enzyme but is rather an inducer of an unknown pathway
that activates elastin-degrading enzymes [49]. These data
are in contrast to our in vitro data clearly showing that in-
soluble elastin may be degraded by MMP-12 but not
MMP-9. The role of MMP-9 in cigarette smoke-induced
COPD was investigated in study including MMP-9 over-
expressing mice, MMP-9 knockout mice, and in patients
that had undergone lung transplantation [50]. Data showed
that MMP-9 expression was not correlated to severity of
disease, albeit in the mouse models an integrated part of
the disease. Our findings show that MMP-9 was not ableFigure 3 Biological validation of ELN-441 in human serum from patie
controls (n = 11). A) Bars indicate mean level. Groups were compared by W
90%. C) Odds ratio. Data are shown as mean ± 1.8SD with 95% confidenceto generate the ELN-441 fragment from insoluble elastin,
when assessed using the ELM assay.
In the present study we identified the ELN-441 bio-
marker as diagnostically sensitive for COPD and IPF, as
compared to controls. This suggests that the hypothesis
stating that lung destruction is driven by MMP-9 and
MMP-12 is valid and can be quantified. The diagnostic
power of ELN-441 was higher for COPD than IPF, which
is in accordance with the recent research in the field of
MMPs and elastin in COPD, and that the main pathologic
problem in IPF might be pulmonary fibrosis and not elas-
tin degradation. However, one complicating factor in the
use of ELN-441 is that elastin expression is not restricted
to the lung tissues, as arteries, skin and tendons have been
shown to express this protein [4]. Thus, several co-
morbidities may influence the systemic levels of ELN-441.
Further investigations are needed to determine each tis-
sue’s contribution to the total pool of the ELN-441 neoepi-
tope, and possibly other ELN epitopes.
One major limitation of the current clinical study of
ELN-441 was the relatively small sample size and the lim-
ited clinical information obtained. Thus these preliminary
findings need to be validated in larger clinical settings for
the diagnostic utility, and also for prognostic potential.
Other researchers have investigated an array of biomar-
kers in induced sputum, exhaled air condensate, bronchial
biopsy, bronchoalveolar lavage fluid, urine and peripheral
blood that could be used as diagnostic and prognostic tools
for lung diseases [51]. There is, however, a relative lack of
information about how these biomarkers relate to disease
severity and to other disease measurements such as FEV1,
how reproducible they are, and how they may be affected
by therapies. Desmosine and isodesmosine have been ex-
tensively discussed as biomarkers of elastin turnover since
they are unique to human elastin. ELISA measurements of
desmosine and isodesmosine in serum have, however, been
shown to be incapable of discriminating between normal
and COPD subjects [14]. Others have investigatednts with COPD (n= 10) and IPF (n = 29) compared with
ilcoxon rank sum test. B) ROC curve; AUCCOPD = 97% and AUCIPF =
intervals.
Figure 4 Release of ELN-441 by MMP-9 and -12 cleavages as a function of time of human elastin from different tissues: A) soluble
elastin, B) non-soluble elastin and C) soluble aorta. The cleaved material was diluted 1:10 in the assay.
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(EDPs), which have been found elevated in plasma of
patients with COPD, but it is unclear whether these pep-
tides reflect elastin turnover in the lung or in other com-
partments of the body such as the arteries [5,10].
Nevertheless, a correlation between EDPs and lung damage
on computed tomographic scans has been shown [9]. EDPs
are detected with use of polyclonal antibodies making the
method less sensitive than assays using monoclonal anti-
bodies. Several other serological biomarkers have been
investigated such as; fibrinogen, C-reactive protein, Trolox
equivalent antioxidant capacity, CXCR2, TGF-beta, TNF-α
[51] and Clara cell secretory protein-16 [52]. Of these, only
C-reactive protein and TNF-α showed a relationship with
FEV1-based disease staging criteria of COPD in a meta-
analysis by Franciosi et al. [53]. However the separation
was small, demonstrating poor sensitivity and diagnostic
potential. Ultimately, a panel of biomarkers may be needed
to characterize different aspects of lung disease in patients,
and for prognosis, diagnosis and assessment of efficacy of
intervention.
The neoepitope technology, measuring of specific
protein degradation fragments, allows for assessment of
specific proteolytic activity in given tissues, provided
that the sequence is unique for one or fewer proteases.
The present assay quantifies the peptide in elastin which
is cleaved at the 441 position, and not the elongated
peptide containing an extra amino acid at the cleavage
site, nor intact elastin. Thus, this assay allows for
quantification of one specific sub-pool of the elastin
molecule—namely the soluble, degraded one. The
sequence was MMP specific, whereas other fragments
identified seems to be specific for aggrecanases and
cathepsins. Other assays will have to be developed to
allow the quantification of these epitopes, providing dif-
ferent biological or pathological information.In conclusion, a robust assay has been developed using a
specific monoclonal antibody for detection of ELN-441, a
MMP-9 and -12 generated fragment of elastin. It was
demonstrated that this fragment was significantly elevated
in COPD and IPF patients and has high diagnostic poten-
tial. Further, larger, clinical studies are needed to confirm
the diagnostic value and also to evaluate the prognostic po-
tential in lung disease, and the potential utility of this neoe-
pitope in other diseases in which elastin degradation may
be a pivotal pathological feature.
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